Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292).

ABSTRACT:

Background

Low post-endocrine Ki67 (Ki67_post) as a marker for endocrine therapy response (ETR) has been shown to be a favorable prognostic factor in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC). So far, all studies have used centralized immunohistochemical measurements. In order to assess the robustness of this marker for clinical routine, we have now compared local and central Ki67 measurements in the WSG ADAPTcycle trial.

Patients and methods

In the WSG ADAPTcycle trial (n = 5292 screened, 1684 randomized; 85 sites in Germany), patients with intermediate-risk EBC based on Oncotype DX and ETR were randomized to (neo)adjuvant chemotherapy followed by endocrine therapy (ET) versus ribociclib + aro

SUBMITTER: Hamann M 

PROVIDER: S-EPMC12391789 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature